Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

BACKGROUND: Type 1 diabetes mellitus is a T-cell-mediated autoimmune disease that leads to a major loss of insulin-secreting beta cells. The further decline of beta-cell function after clinical onset might be prevented by treatment with CD3 monoclonal antibodies, as suggested by the results of a ph...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak:	Keymeulen, B, Vandemeulebroucke, E, Ziegler, A, Mathieu, C, Kaufman, L, Hale, G, Gorus, F, Goldman, M, Walter, M, Candon, S, Schandene, L, Crenier, L, De Block, C, Seigneurin, J, De Pauw, P, Pierard, D, Weets, I, Rebello, P, Bird, P, Berrie, E, Frewin, M, Waldmann, H, Bach, J, Pipeleers, D, Chatenoud, L
Formatua:	Journal article
Hizkuntza:	English
Argitaratua:	2005

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Antzeko izenburuak